Company Profile
Passage Bio Stock Price, News & Analysis
- Ticker:
- PASG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.40 USD (-4.56%)
Close
Last updated: August 6, 2026
18.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PASG closed down 4.56% at $4.40. No new same-company headline was identified in the current news window.
Company overview
Business overview
Passage Bio is a gene-therapy company focused on rare and neurological diseases. Its business has centered on the challenge of translating genetic medicine into the central nervous system.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Passage sits in advanced biotechnology.
Business Model Characteristics
The company depends on clinical data, delivery science, and the ability to create value in rare genetic disease.
Position Within the Biotechnology Landscape
Passage is a high-catalyst gene-therapy name whose valuation is tied to early clinical outcomes.
Future catalysts
Passage Bio’s catalysts are its rare-CNS gene-therapy programs and any strategic update that clarifies which assets still matter. The company needs stronger clinical clarity.
Recent news
- 01
Passage Bio and Remix Therapeutics Announce Merger Agreement
Source: Passage Bio
- 02
- 03
- 04
Passage Bio to Participate in Upcoming Investor Conferences
Source: Passage Bio
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Passage Bio (PASG)?
Passage Bio (PASG) most recently closed at 4.40 USD, a -4.56% move versus the previous session.
What is the market cap of Passage Bio (PASG)?
Passage Bio currently has a market capitalization of 18.9M USD on BioPharmSignal.
What does Passage Bio do?
Passage Bio is a gene-therapy company focused on rare and neurological diseases. Its business has centered on the challenge of translating genetic medicine into the central nervous system.
On which exchange is PASG stock listed?
Passage Bio (PASG) is associated with NASDAQ, United States, Biopharma.
What is Passage?
Passage Bio’s catalysts are its rare-CNS gene-therapy programs and any strategic update that clarifies which assets still matter.
Which conditions is Passage Bio targeting with Passage?
Passage Bio is associated with genetic disease based on its company overview and current catalyst commentary.
How does Passage Bio describe recent progress with Passage?
Passage Bio’s catalysts are its rare-CNS gene-therapy programs and any strategic update that clarifies which assets still matter.
What future catalysts are investors watching for Passage Bio?
Passage Bio’s catalysts are its rare-CNS gene-therapy programs and any strategic update that clarifies which assets still matter. The company needs stronger clinical clarity.